Cymabay Therapeu Stock Book Value Per Share
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay Therapeu fundamentals help investors to digest information that contributes to Cymabay Therapeu's financial success or failures. It also enables traders to predict the movement of Cymabay Stock. The fundamental analysis module provides a way to measure Cymabay Therapeu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cymabay Therapeu stock.
Cymabay |
Cymabay Therapeu Company Book Value Per Share Analysis
Cymabay Therapeu's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Cymabay Therapeu Book Value Per Share | 2.57 X |
Most of Cymabay Therapeu's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cymabay Therapeu is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Cymabay Therapeu is about 2.567 times. This is 251.0% lower than that of the Pharmaceuticals sector and 101.03% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.87% higher than that of the company.
Cymabay Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cymabay Therapeu's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cymabay Therapeu could also be used in its relative valuation, which is a method of valuing Cymabay Therapeu by comparing valuation metrics of similar companies.Cymabay Therapeu is currently under evaluation in book value per share category among its peers.
Cymabay Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (745.58) % | |||
| Current Valuation | 3.45 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 0.51 % | |||
| Shares Owned By Institutions | 99.49 % | |||
| Number Of Shares Shorted | 5.85 M | |||
| Price To Earning | (8.62) X | |||
| Price To Book | 12.76 X | |||
| Price To Sales | 119.98 X | |||
| Revenue | 31.07 M | |||
| Gross Profit | (41.63 M) | |||
| EBITDA | (101 M) | |||
| Net Income | (105.37 M) | |||
| Cash And Equivalents | 153.42 M | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 114.49 M | |||
| Debt To Equity | 1.45 % | |||
| Current Ratio | 12.20 X | |||
| Book Value Per Share | 2.57 X | |||
| Cash Flow From Operations | (72.53 M) | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (0.99) X | |||
| Target Price | 32.5 | |||
| Number Of Employees | 101 | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.73 B | |||
| Total Asset | 434.69 M | |||
| Retained Earnings | (978.23 M) | |||
| Working Capital | 366.96 M | |||
| Current Asset | 42.79 M | |||
| Current Liabilities | 6.15 M | |||
| Z Score | 16.7 | |||
| Net Asset | 434.69 M |
About Cymabay Therapeu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cymabay Therapeu's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cymabay Therapeu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cymabay Therapeu based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |